Cardiac Vagal Activation by Adrenocorticotropic Hormone Treatment in Infants with West Syndrome

AYAKO HATTORI,1 JUNICHIRO HAYANO,2 SHINJI FUJIMOTO,1 NAOKI ANDO,1 KUMIKO MIZUNO,3 MICHIO KAMEI,1 SATORU KOBAYASHI,1 TATSUYA ISHIKAWA1 and HAJIME TOGARI1

1Department of Pediatrics, Neonatology and Congenital Disorders, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
2Medical Education, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan
3Department of Central Clinical Laboratory, Nagoya City University Hospital, Nagoya, Japan


West syndrome (WS) is a generalized epileptic syndrome of infancy and early childhood with various etiologies, and consists of a triad of infantile spasm, arrest or regress of psychomotor development and specific electroencephalogram (EEG) pattern of hypsarrhythmia. WS had been believed to be refractory, but recent evidence supports effectiveness of adrenocorticotropic hormone (ACTH) treatment. The ACTH treatment, however, has a problem that it is often accompanied by adverse autonomic symptoms. We therefore examined heart rate variability (HRV) for assessing cardiac autonomic functions in WS and prospectively observed the changes during ACTH treatment. We studied 15 patients with WS and 9 age-matched controls during sleep (EEG stage 2). Compared with controls, the patients with WS were greater in the low-frequency component (LF) of HRV, an index reflecting sympatho-vagal interaction (p = 0.02), but were comparable for high-frequency component (HF) and LF-to-HF ratio (LF/HF), indices reflecting cardiac vagal activity and sympathetic predominance, respectively. During ACTH treatment, heart rate decreased (p < 0.01), LF and HF increased (p < 0.01), and LF/HF did not differ significantly. These results indicate that West syndrome might be accompanied by autonomic changes and that ACTH treatment enhances parasympathetic function and causes bradycardia.

© 2007 Tohoku University Medical Press
but the mechanism is unclear (Hamano et al. 2005). Although these findings suggest that autonomic abnormalities are involved in the pathophysiology of WS, convincing evidence is not yet available.

The present study investigates whether patients with WS have abnormalities in objective measures of autonomic function and, if so, whether ACTH can modify them. We evaluated autonomic functions by performing spectral analysis of heart rate variability (HRV), which is a physiological arrhythmia generated by autonomic modulations of sinus nodal automaticity that non-invasively and quantitatively assesses autonomic functions. The high-frequency component (HF, at around breathing frequency) of HRV is mediated purely by the vagus and reflects respiratory fluctuation of cardiac vagal activity. The low-frequency component (LF, 0.04-0.15 Hz) is mediated by both sympathetic and vagal activities and thus the LF-to-HF ratio (LF/HF) is used as an index of sympathetic relative to vagal predominance (Pomeranz et al. 1985; Pagani et al. 1986; Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology 1996). Here, we compared these HRV measures during non rapid eye movement (NREM) sleep stage 2 in EEG between controls and patients with WS. We determined whether HRV values are altered in patients with WS and prospectively observed whether synthetic ACTH can modify them.

**METHODS**

**Patients**

We studied 19 consecutive patients with WS who were less than two years of age. They were admitted to Nagoya City University Hospital between Jan 2003 and Dec 2005 and treated with synthetic ACTH because oral antiepileptic drugs were ineffective against tonic spasms. Patients were excluded if they had congenital cardiac anomalies or atrial fibrillation, or they were prescribed with antiarrhythmic agents. Written informed consent was obtained from at least one of each parent.

**Controls**

Nine children aged less than 2 years of age (8 boys and 1 girl) who were suspected of having epilepsy but had no significant pathological problems underwent EEG. Two of them were diagnosed as having benign infantile epilepsy, one had febrile convulsion, and six had no neurological abnormalities. None of them had either developmental delay or EEG abnormalities. The mean age of the controls was 8.7 months, which did not differ from that of the patient group.

**Protocols**

All procedures of this study were conducted according to the guidelines of the Declaration of Helsinki.

**ACTH treatment**

Synthetic corticotrophin (0.015 mg/kg daily for symptomatic WS and 0.5 mg [20 IU]/m² daily for cryptogenic WS) was administered and continued until the spasms and hypsarrhythmic EEG patterns disappeared. The drug was stopped without tapering if administered for less than 15 days. When the duration of ACTH administration was over 15 days, the same daily dose of ACTH was given once every other day three times. The maximal duration of consecutive ACTH administration was 21 days (Hattori et al. 2006).

**EEG and ECG measurements**

We simultaneously measured EEGs and ECGs during NREM sleep stage 2 using a digital EEG polygraph (Nihon Kohden, Tokyo) between 10 a.m. and 3 p.m. Most of the infants received triclofos sodium before the recordings were obtained. None of the children suffered seizures within more than 30 min before recording. Sleep stage 2 was defined as the presence of 12-14 Hz spindles. We examined ECGs that were measured for 6 to 8 consecutive min during NREM sleep stage 2. Among the patients with WS, polygraphic measurements were taken before, on the 7th and last days of administration and one week after the end of ACTH administration.

**Analysis of HRV**

The digital ECG data were analyzed using a personal computer. All QRS complexes were initially detected using a fast peak detection algorithm. The results of the analysis were reviewed and any errors in R-wave detection were manually edited. Secondly, all QRS complexes were classified into normal beats (sinus rhythm) or not (ectopic or blocked) and then time series of R-R intervals were generated using only consecutive normal-to-normal intervals. ECGs waveforms were complete and any
We calculated HR from mean R-R intervals. To assess HRV, the power spectral density of R-R interval variability was computed by fast Fourier transformation. Thereafter, the power of two frequency regions was computed by integrating the power spectral density within the respective frequency bands; i.e., 0.04-0.15 Hz for the LF component and 0.30-1.30 Hz (which covered the breathing frequencies of all subjects) for the HF component. The powers of the LF and HF components were transformed into natural logarithmic values to normalize the distribution of the values.

Statistical analysis

We used the SPSS (version 13.0) software package for all statistical analysis. The Mann-Whitney’s U-test was applied to between-group comparisons. Changes in HR and HRV parameters before, during (the seventh and last days) and after ACTH treatment were analyzed using the one-way analysis of variance (ANOVA) with repeated measures and the Bonferroni method was used to adjust for multiple comparisons. All tests were two-tailed; a value of $p < 0.05$ was considered statistically significant. Data are presented as means ± s.d. in the text and as means and s.e. of the mean in the figures.

RESULTS

Study patients

Among 19 patients with WS, two were excluded from the study due to congenital cardiac anomalies (large ventricular septal defect and double-outlet right ventricle, respectively) and two others were excluded due to the absence of adequate records. Among 15 patients (9 boys and 6 girls), 11 had symptomatic WS and 4 had cryptogenic WS (Table 1). Their mean age was 9.9 months (range, 5.4-23.4 months) and the mean duration of ACTH treatment was 14.3 days (range, 8-21 days). The administrations of antiepileptic drugs in Table 1 were continued in most patients during ACTH treatment. All patients had no seizures and had no hypsarrhythmia in EEGs on the last day of ACTH and after ACTH. None of patients had subdural hemorrhages after ACTH.

**Table 1. Profiles of Patients with West syndrome (WS).**

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Etiology</th>
<th>Age at start of ACTH treatment (months)</th>
<th>Duration of ACTH (days)</th>
<th>Medication during study</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Fetal hypoxia</td>
<td>8.5</td>
<td>11</td>
<td>ZNS, CZP</td>
</tr>
<tr>
<td>2</td>
<td>Periventricular leukomalacia</td>
<td>8.6</td>
<td>14</td>
<td>ZNS, CLB</td>
</tr>
<tr>
<td>3</td>
<td>Periventricular leukomalacia</td>
<td>14.4</td>
<td>14</td>
<td>ZNS, CZP</td>
</tr>
<tr>
<td>4</td>
<td>Aicardi syndrome</td>
<td>6.5</td>
<td>17</td>
<td>VPA, PB, NZP</td>
</tr>
<tr>
<td>5</td>
<td>Holocarboxylase synthetase deficiency</td>
<td>23.4</td>
<td>14</td>
<td>ZNS, CZP</td>
</tr>
<tr>
<td>6</td>
<td>Periventricular leukomalacia</td>
<td>15.0</td>
<td>21</td>
<td>PB, ZNS, VPA</td>
</tr>
<tr>
<td>7</td>
<td>Tuberos sclerosis</td>
<td>7.2</td>
<td>21</td>
<td>ZNS, CZP, VPA</td>
</tr>
<tr>
<td>8</td>
<td>Psychomotor delay with unknown cause</td>
<td>7.3</td>
<td>21</td>
<td>ZNS</td>
</tr>
<tr>
<td>9</td>
<td>Tuberos sclerosis</td>
<td>14.1</td>
<td>14</td>
<td>ZNS, CZP</td>
</tr>
<tr>
<td>10</td>
<td>Neonatal hypoglycemia</td>
<td>8.1</td>
<td>10</td>
<td>ZNS</td>
</tr>
<tr>
<td>11</td>
<td>Psychomotor delay with unknown cause</td>
<td>10.7</td>
<td>14</td>
<td>ZNS, CZP</td>
</tr>
<tr>
<td>12</td>
<td>Cryptogenic</td>
<td>6.2</td>
<td>8</td>
<td>None</td>
</tr>
<tr>
<td>13</td>
<td>Cryptogenic</td>
<td>5.4</td>
<td>12</td>
<td>ZNS</td>
</tr>
<tr>
<td>14</td>
<td>Cryptogenic</td>
<td>8.0</td>
<td>11</td>
<td>CBZ, ZNS</td>
</tr>
<tr>
<td>15</td>
<td>Cryptogenic</td>
<td>5.8</td>
<td>21</td>
<td>ZNS</td>
</tr>
</tbody>
</table>

Mean ± s.d. 9.9 ± 4.9 14 ± 4

ZNS, zonisamide; CZP, clonazepam; CLB, clobazam; VPA, valproate sodium; PB, phenobarbital; NZP, nitrazepam; CBZ, carbamazepine.
Comparison between WS patients and controls

Differences in HR and HRV measurements between patients with WS and controls were compared using the data before ACTH treatment (Fig. 1). The EEGs in all subjects showed sinus rhythm. The HR did not differ significantly between patients and controls (mean ± s.d.: 113 ± 15 and 120 ± 10 bpm). The LF power was greater in patients with WS than in controls (5.8 ± 1.4 and 4.5 ± 0.9 ln ms², \( p = 0.02 \)), whereas the difference in the HF power did not reach statistical significance (5.7 ± 2.0 and 4.5 ± 1.4 ln ms²). The LF/HF ratio was comparable between patients and controls (1.7 ± 1.3 and 1.7 ± 1.4). Although we compared cryptogenic and symptomatic groups, none of HR, LF power, HF power, and LF/HF ratio before ACTH significantly differed.

Change in HR and HRV measures during ACTH treatment

Fig. 2 shows the power spectra of the R-R interval in a representative patient with WS before and during ACTH treatment. The power of the HF component was obviously increased during the treatment.

Fig. 3 shows changes in HR and HRV values induced by ACTH. During ACTH treatment, HR was decreased and the LF and HF powers were
increased \( (p < 0.001 \text{ for all}) \). These effects were significant at both the seventh and last days of ACTH treatment but were no longer evident one week after the end of treatment. Treatment with ACTH did not significantly change the LH/HF ratio.

**DISCUSSION**

We demonstrated here that patients with WS had greater LF power than controls and that ACTH treatment caused a decrease in HR and increases in both LF and HF power of HRV in the patients. The former finding suggests that WS is associated with altered cardiac autonomic function and the latter, that ACTH caused a remarkable increase in cardiac vagal activity and resultant bradycardia in these patients. This is the first study to demonstrate evidence of cardiac vagal activation and bradycardia during ACTH treatment.

We analyzed HRV during sleep stage 2 determined by simultaneous EEG. In general, evaluations of autonomic functions are difficult in infants due to uncooperativeness and/or continuous movement of the subjects. Thus, most previous studies of HRV in this population have been performed using ambulatory ECG or while the subjects are asleep. However, the former could be affected by the level and diurnal pattern of activities and the latter by the stage or quality of sleep (Finley and Nugent 1995; Sanada et al. 1996; Goto et al. 1997; Massin and von Bernuth 1997; Yang et al. 2001; Ferri et al. 2002; Mehta et al. 2002). Given that epilepsy and associated neural disorders affect daily activities and sleep, our method seems advantageous not only for assessing autonomic functions under standardized conditions but also for detecting changes that are directly relevant to diseases or drug effects.

Our observation of increased power of the LF component in patients with WS might reflect a component of autonomic dysfunction that is commonly associated with generalized epilepsies (Devinsky et al. 1994; Opherk et al. 2002; Devinsky 2004). West syndrome is regarded as a form of generalized epilepsy characterized by hypsarrythmia. Evrengul et al. (2005) demonstrated that patients with generalized tonic-clonic seizures have changes in HRV including increased LF power, although they also observed decreased power and increased LF/HF. We believe that etiological factors might not affect autonomic function, because the cryptogenic and symptomatic groups in the present study did not significantly
differ. However, the distribution of LF power in the WS and control groups overlapped, indicating that some patients with WS do not have autonomic changes. Further study is needed to clarify this point.

The key finding of this study is that ACTH treatment in patients with WS causes bradycardia and changes in HRV that are consistent with cardiac vagal activation. Surprisingly, bradycardia has not been reported as a side effect of ACTH treatment, although Hamano et al. (2005) have described two patients who suddenly died during ACTH treatment. Nevertheless, cardiac vagal activation and resultant bradycardia represent a plausible potential cause of death among patients with epilepsy (Hirsch and Martin 1971; Tennis et al. 1995; Tomson et al. 1998; Nei et al. 2004). Although the administration of antiepileptic drugs except for ACTH was not changed and HR and HRV parameters did not significantly differ between before and after ACTH, the HR and HRV parameters were altered during ACTH treatment. These observations indicate that the pharmacokinetic action of ACTH affects autonomic function.

The mechanisms of vagal activation during ACTH treatment remain undetermined, but the suppression of corticotropin-releasing hormone (CRH) by ACTH might be involved. The systemic administration of ACTH decreases the expression of CRH, which stimulates sympathetic outflow and inhibits parasympathetic outflow (Brown et al. 1982; Fisher et al. 1983; Wiersma et al. 1993; Brunson et al. 2001; Wang et al. 2004). These facts suggest that ACTH enhances vagal activity in patients with WS at least partly through CRH suppression.

Others have found that 3 to 5% of patients treated with ACTH die and that these patients tend to have received large doses of ACTH (Riikonen 2001; Hamano et al. 2004). Most protocols of ACTH treatment for WS indicate that ACTH should be administered for more than 14 days and then tapered (Yanagaki et al. 1999; Mackay et al. 2004). Because longer ACTH treatment is associated with more side effects including hypertension, infection, subdural hemorrhage and brain atrophy, some investigators have recommended a shorter duration of ACTH treatment (Ito et al. 1990; Hrachovy et al. 1994; Kondo et al. 2005; Oguni et al. 2006).

In addition to these known side effects, the present study also suggests that obvious cardiac vagal activation and bradycardia are also important side effects that require more clinical consideration. Furthermore, we found that these effects appear within 7 days of ACTH treatment and persist until the end of treatment. However, these effects seem reversible as they disappeared within a week after withdrawing treatment.

In conclusion, we identified changes in cardiac autonomic functions in patients administered with ACTH, by analyzing HRV under the standardized conditions of sleep stage 2. Consistent with other generalized types of epilepsy our findings indicated that WS is associated with altered autonomic functions and that ACTH treatment in patients with WS causes marked cardiac vagal activation and resultant bradycardia. These potential mechanisms could explain some of the adverse effects of ACTH therapy.

References
Cardiac Vagal Activation by ACTH in West Syndrome


